Clinical trial
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
NCT00002435 · Pharmacia, Industry · Completed
Key facts
| NCT number | NCT00002435 |
|---|---|
| Title | A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients |
| Official title | Study of the Activity of Thymic Humoral Factor (THF Gamma 2) on HIV Load in HIV-Positive Individuals With CD4+ Cell Counts in the Range of 200-500 Cells/mm3 |
| Lead sponsor | Pharmacia, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Thymic Humoral Factor, Zidovudine |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: